Fibrogen Inc (FGEN): Thomas B Neff , director officer 10% owner (Chief Executive Offic of Fibrogen Inc sold 27,000 shares on May 2, 2016. The Insider selling transaction was reported by the company on May 3, 2016 to the Securities and Exchange Commission. The shares were sold at $17.78 per share for a total value of $480,060.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 20, 2016, Thomas B Neff (director officer 10% owner (Chief Executive Offic) sold 27,000 shares at $19.98 per share price.On Apr 4, 2016, Frank H Md Valone (Chief Medical Officer) sold 10,750 shares at $21.29 per share price.Also, On Jan 22, 2016, Thomas F Jr Kearns (director) sold 1,572 shares at $22.08 per share price.On Dec 17, 2015, Pat Cotroneo (VP, Finance and CFO) sold 837 shares at $28.95 per share price.
FibroGen Inc: On Monday, May 2, 2016 heightened volatility was witnessed in FibroGen Inc which led to swings in the share price. The shares opened for trading at $18.18 and hit $18.45 on the upside , eventually ending the session at $18.37, with a gain of 2.06% or 0.37 points. The heightened volatility saw the trading volume jump to 3,96,286 shares. The 52-week high of the share price is $31.9 and the company has a market cap of $1,140 M . The 52-week low of the share price is at $14.38.
Company has been under the radar of several Street Analysts.FibroGen Inc is Upgraded by Credit Suisse to Outperform and the brokerage firm has set the Price Target at $40. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Feb 11, 2016.
FibroGen Inc. is a research-based biopharmaceutical company. The Company is focused on the discovery development and commercialization of therapeutic agents. Its lead product candidate is roxadustat or FG-4592 is an oral small molecule inhibitor of hypoxia inducible factor-prolyl hydroxylase (HIF-PHs) in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). The Company’s second product candidate FG-3019 is a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) pancreatic cancer and liver fibrosis. Roxadustat is a HIF-PH inhibitor that acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-5200 is a corneal implant. Its product FG-3019 blocks FG-3019 blocks CTGF (CTGF). FG-6874 is a HIF-PH inhibitor. FG-8205 is in preclinical evaluation for use as a cardioprotective agent to prevent the onset of heart failure following a heart attack.